Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors by Karjalainen, S L et al.
RESEARCH ARTICLE Open Access
Carbonic anhydrase related protein
expression in astrocytomas and
oligodendroglial tumors
Sini L. Karjalainen1* , Hannu K. Haapasalo2, Ashok Aspatwar1,2, Harlan Barker1, Seppo Parkkila1,2
and Joonas A. Haapasalo1,2,3
Abstract
Background: Carbonic anhydrase related proteins (CARPs) VIII, X and XI functionally differ from the other carbonic
anhydrase (CA) enzymes. Structurally, they lack the zinc binding residues, which are important for enzyme activity
of classical CAs.
The distribution pattern of the CARPs in fetal brain implies their role in brain development. In the adult brain,
CARPs are mainly expressed in the neuron bodies but only weaker reactivity has been found in the astrocytes and
oligodendrocytes. Altered expression patterns of CARPs VIII and XI have been linked to cancers outside the central
nervous system.
There are no reports on CARPs in human astrocytomas or oligodendroglial tumors. We wanted to assess the
expression of CARPs VIII and XI in these tumors and study their association to different clinicopathological features
and tumor-associated CAs II, IX and XII.
Methods: The tumor material for this study was obtained from surgical patients treated at the Tampere University
Hospital in 1983–2009. CARP VIII staining was analyzed in 391 grade I-IV gliomas and CARP XI in 405 gliomas.
Results: CARP VIII immunopositivity was observed in 13% of the astrocytomas and in 9% of the
oligodendrogliomas. Positive CARP XI immunostaining was observed in 7% of the astrocytic and in 1% of
the oligodendroglial tumor specimens. In our study, the most benign tumors, pilocytic astrocytomas, did not express
CARPs at all. In WHO grade II-IV astrocytomas, CARPs were associated with molecular events related to more benign
behavior, which was the case with CARP VIII in oligodendrogliomas and oligoastrocytomas as well.
Conclusions: The study observations suggest that the CARPs play a role in tumorigenesis of diffusively
infiltrating gliomas. Furthermore, the molecular mechanisms beneath the cancer promoting qualities of CARPs have
not yet been discovered. Thus, more studies concerning role of CARPs in oncogenesis are needed.
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Background
Carbonic anhydrases (CAs) catalyze the reversible con-
version of carbon dioxide and water to bicarbonate ion
and proton. These enzymes are fundamental in normal
physiological processes in organisms [1, 2]. The role of the
CAs in diseases has been investigated extensively, and at
least CA II, IX and XII have been associated to neoplastic
growth [3–5].
Three inactive CA isoforms were discovered in 1990s
and were named carbonic anhydrase related proteins
(CARPs) VIII, X, and XI [1, 6]. They lack the one or more
of the three zinc binding histidine residues which are re-
quired for the enzymatic activity of CAs [1]. The distribu-
tion pattern of CARPs in adult and fetal brain implies a
role in brain development [7]. In the human enteric ner-
vous system, CARP VIII and X are expressed in neural cell
bodies, whereas CARP XI is absent [7]. In the human
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central nervous system (CNS), weak but significant CARP
X mRNA expression has been detected in almost all parts
of the system, whereas it is absent in the fetal brain and
other developing tissues. In the fetal brain, CARP VIII and
XI expression has been detected first at the 84th day of
gestation in the neuroprogenitor cells. Later expression
has been found in the migrating neural cells. CARP X ex-
pression has been observed in the cerebral cortical neu-
rons at the 141st day of gestation [8].
Immunohistochemical analysis has shown strong ex-
pression of CARP VIII in neuron bodies of almost all
parts of the adult brain. Weak reactivity was observed in
the astrocytes, while the expression was completely ab-
sent in the oligodendrocytes. Choroid plexus and pia
arachnoid have been strongly positive for CARP VIII. The
CARP XI expression is weaker than CARP VIII, but the
overall distribution among the neurons and glial cells is
similar. CARP X expression differs from the other CARPs;
it has been found mainly in the myelin sheath of the oligo-
dendrocytes, and only weak expression has been detect-
able in the Purkinje cells and neurons of olivary nuclei [8].
CARP VIII is predominantly expressed in cerebellar
Purkinje cells and appears to modulate IP3-induced
calcium release in these cells [9, 10]. A homozygous mis-
sense mutation in human CA8 gene that codes for CARP
VIII, leads to reduction in cerebellar volume causing mild
mental retardation and cerebellar ataxia and some patients
exhibit quadrupedal gait [11, 12]. In waddles mice, Car8
gene mutation and the consequential protein deficiency
are associated with obtrusive gait disorder [13]. In zebra-
fish, knockdown of the CA8 gene leads to reduction in
cerebellar volume and abnormal swim pattern, which are
similar to the consequences of CA8 gene mutation in
humans and mice [14]. Thus, CARP VIII plays an import-
ant role in motor control in humans, mice and zebrafish.
The function of CARP X and XI is unclear in humans.
However, expression studies in humans show that CARP
X is highly expressed in pineal gland at night suggesting
its role in circadian rhythm (day-night cycle) [15]. The
5′-untranslated region of the CA10 gene contains a CCG
trinucleotide repeat in normal humans. The presence of
CCG repeats in the CA10 gene indicates that CARP X
could be involved in neurologic disorders due to muta-
tions expanding the number of repeats [16]. Studies in
humans and cultured cells showed that CARP XI is asso-
ciated with spinocerebellar ataxia 3/Machado Joseph’s dis-
ease [17]. The latest studies on CARP X and CARP XI in
zebrafish showed that these genes are predominantly
expressed in CNS, and knockout of these genes induces to
apoptosis in the brain leading to ataxic swim pattern in
the ca10a and ca10b mutant zebrafish [18].
Altered expression patterns of CARPs VIII and XI
have been also linked to cancer. CARP VIII has been
reported to promote colon cancer cell growth and
invasiveness [19]. In colorectal adenocarcinomas,
strong expression of CARP VIII has been found at the
tumor infiltrative border [20]. In lung adenocarcinoma
cells, CARP VIII increases cell growth in a laminin-rich
environment, which led to a hypothesis that it may inter-
rupt apoptosis signaling [21]. Strong CARP VIII expres-
sion has been observed in the developing fetal lung and at
the infiltrative border of the non-small cell lung carcin-
oma, but only minor expression has been found in the
adult lung [22]. Most of the gastrointestinal stromal tu-
mors (GIST) overexpress both CARP VIII and XI, and es-
pecially CARP XI seems to enhance proliferation and
invasion of these tumors [23]. Similar to the lung and
colorectal cancers, the most intense expression of CARPs
VIII and XI is present in the marginal areas rather than
the center of the GISTs [23].
Recent study showed an increased expression of CA8
gene in more aggressive types of human osteosarcoma
(HOS) cells and the CA8 expression correlated with the
disease stages, showing intense expression in the late
stages of the disease. Further experiments involving over-
expression of CA8 gene in HOS cells showed significant
increase in cell proliferation both in vitro and in vivo.
Interestingly, downregulation of CA8 gene in HOS cells
decreased cell invasion and colony formation ability in soft
agar, and reduced the expression of metalloproteinase 9
(MMP9) and focal adhesion kinase (FAK), suggesting a
role for CARP VIII in cancer cell invasion through the ac-
tivation of FAK-MMP9 signaling [24]. Even though several
tumors overexpress CARPs, the exact molecular mecha-
nisms beneath their cancer promoting qualities have not
yet been discovered [19, 23].
In the case of brain tumors, there have been no re-
ports on CARPs in human astrocytomas and oligo-
dendroglial tumors (oligodendrogliomas and
oligoastrocytomas). These tumors derive from glial cells
or glial progenitor cells and the majority of them are
highly malignant. The surgical treatment is often inad-
equate and the prognosis of patients is still poor [25,
26]. Because the progenitor cells have been shown to ex-
press CARPs during fetal development, we wanted to as-
sess the expression of different CARPs in astrocytomas,
oligodendrogliomas and oligoastrocytomas, and to study
their association with different clinicopathological fea-
tures and patient survival. Since CAs II, IX and XII have
shown high expression in gliomas, their association with
CARPs was also evaluated.
Methods
Materials
The tumor material was obtained from surgical patients
treated at the Tampere University Hospital in 1983–
2004 (astrocytomas) and in 1983–2009 (oligodendroglial
tumors). The study was approved by the research ethics
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committee of Tampere University Hospital. Brain tumor
specimens fixed in 4% phosphate-buffered formaldehyde
were processed into paraffin blocks. The tissue sections
were stained with hematoxylin and eosin and then evalu-
ated according to the WHO 2007 criteria [27] by a
neuropathologist. A sample from a histologically repre-
sentative tumor region was included in multi-tissue
blocks constructed with a custom-built instrument (Bee-
cher Instruments, Silver Spring, MD, USA). The tissue
cores were 600 μm in diameter.
There were 327 diffusely infiltrating astrocytoma
(WHO grades II-IV) samples of which 255 were primary
tumors and 72 were recurrences. The ages of patients
with primary tumors varied from 17 to 91 years (mean
64). In addition, the material included 31 grade I pilocy-
tic astrocytomas (20 primaries of age 11–74 (mean 24)
years, and 11 recurrences).
The oligodendroglial tumor (WHO grades II-III)
group included 86 tumor samples, of which 69 were
primary tumors and 17 were recurrences. The ages of
patients with primary tumors varied from 5 to 74 (mean
49) years.
Immunohistochemistry
Automated immunostaining for CARP VIII and XI was
performed using BrightVision+ Poly-HRP-Anti IHC Kit
(Poly-HRP-Anti-mouse/rabbit/rat IgG immunohisto-
chemistry kit; ImmunoLogic, Duiven, The Netherlands)
reagents. The immunostaining method included the fol-
lowing steps: (a) rinsing in wash buffer; (b) treatment in
3% hydrogen peroxide in double-distilled water (ddH2O)
for 5 min and rinsing in wash buffer; (c) blocking with
cow colostrum diluted 1:5 in dH2O for 10 min and rins-
ing in wash buffer; (d) incubation with rabbit polyclonal
anti-CA VIII or anti-CA XI antibodies (Santa Cruz Bio-
technology CA VIII: SC-67330 Lot#A2808, CA XI:
SC-67333 Lot#A2808) both diluted 1:250 in Univer-
sal IHC Blocking/Diluent (ImmunoLogic Normal
Antibody Diluent) for 30 min. The brain tumor speci-
mens have also been immunostained with antibodies
against CA IX (positive controls) and normal rabbit serum
(negative controls) as previously described [28]; (e) rinsing
in wash buffer for 3 × 5 min; (f) incubation in poly-HRP–
conjugated anti-rabbit immunoglobulin G for 30 min and
rinsing in wash buffer for 3 × 5 min; (g) incubation
in 3,3′-diaminobenzidine tetrahydrochloride (Vector
ImmPact DAB) solution (1 drop of ImmPACT™ DAB
Chromogen concentrate to 1 ml ImmPACT™ DAB Dilu-
ent) for 5 min; (h) rinsing with water; (i) copper(II) sulfate
treatment for 5 min to enhance the signal; (j) rinsing in
wash buffer; (k) rinsing with 1/3 hematoxylin/ddH2O for
one minute. All procedures were carried out at room
temperature.
The intensity of cytoplasmic staining reactions was
scored from the tissue microarrays on a scale from 0 to
3: 0, no reaction; 1 (+), weak reaction; 2 (++), moderate
reaction; and 3 (+++), strong reaction. In the statistical
analyses, the specimens were grouped into two large cat-
egories based on the staining: CARP-positive tumors
with weak, moderate or strong immunostaining and
CARP-negative tumors with negative immunostaining
results. EGFR amplification was detected with EGFR
chromogenic in situ hybridization (CISH) as described
previously described [29]. In the analysis immunoposi-
tivity of VEGF, EGFR and CA II is marked as 1, negative
immunostaining is marked as 0.
Statistical analysis
All of the statistical analyses were performed using SPSS
for Windows (SPSS 20.0, Chicago, IL, US). The signifi-
cances of associations were defined using the chi-square
test. The significance of associations was defined using
χ2 test.
FANTOM expression of CARP genes
The functional annotation of the mammalian genome
(FANTOM) project has performed expression analysis
on 1839 samples from 573 primary cells, 152 tissues,
and 250 cell lines in human. Specifically, the data comes
from cap analysis gene expression (CAGE) sequencing
of cDNA [30]. We retrieved expression values for CA8
and CA11 from the FANTOM database (http://fan-
tom.gsc.riken.jp/5/sstar/) in units of normalized tags per
million (TPM).
Computational analysis of transcription factor binding
sites in CARP promoters
A computational comparative genomics analysis was
performed on the promoter region of the human CA8
(Ensembl: ENSG00000178538) and CA11 (Ensembl:
ENSG00000063180) genes, defined as the region 800
nucleotides (nt) upstream and 200 nt downstream of
the transcription start site (TSS). There is currently
just one CA8 transcript identified as protein coding,
ENST00000317995, which encodes the full-length 290
amino acid (aa) CA8 protein. There are two CA11 tran-
scripts, yet only one, ENST00000084798, expresses the
full-length 328aa CA11 protein. A second transcript,
ENST00000596080, produces a truncated 113aa CA11
protein. In our analysis we only addressed the CA11 tran-
script corresponding to the full-length protein.
For both CA8 and CA11 transcripts, an alignment of
the corresponding promoter nucleotide sequences of
available mammalian species (including human) was re-
trieved from the Ensembl database, 17 species and 24
species, respectively. Using the Python tool tfbs_foot-
printer from the TFBS_footprinting package (https://
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pypi.python.org/pypi/TFBS-footprinting), experimentally
determined binding sites for transcription factors (TFs)
from the Jaspar database [31] were used to construct
position weight matrices and subsequent log likelihood
scoring of potential transcription factor binding sites
(TFBSs). After scoring all possible positions in the nu-
cleotide sequences of all species, locations where high
scoring potential TFBSs were observed in multiple spe-
cies were identified.
Results and discussion
The cellular origin of the gliomas has been a focus of in-
tensive research for decades. Many recent studies have
implied that the neural stem cells can initiate and main-
tain the growth of human brain tumors, and hence
could act as considerable targets for therapy [25]. In the
development of CNS, fetal neuroprogenitor cells express
CARP VIII and XI [8]. Mature oligodendrocytes, exclud-
ing the myelin sheath, do not express CARPs at all. As-
trocytes have shown weak expression of CARPs VIII and
XI [8]. The presence of CARPs in both the fetal brain
and some tumors suggests that they might represent
oncofetal proteins and play a role in the development of
gliomas.
In this study, we first evaluated the expression of
CARPs VIII, X and XI in astrocytomas, oligodendrogliomas
and oligoastrocytomas by immunohistochemistry. Because
the expression of CARP X turned out to be extremely low
in gliomas, it was excluded from the final analyses. Some
representative images of CARP VIII and XI staining are
shown in Fig. 1.
CARP VIII staining was analyzed in 391 grade I-IV gli-
omas and CARP XI in 405 gliomas (Table 1). Of these
no CARP immunostaining was observed in grade I pilo-
cytic astrocytomas (excluded in the further analyses).
In further statistical analysis the grade II – IV gliomas
with inconclusive genetic testing (according WHO 2016
CNS tumor classification) were also excluded. The ex-
cluded tumors are marked as NOS (not otherwise speci-
fied) tumors in the Table 1.
In diffuse astrocytic and oligodendroglial tumors
tested for the appropriate molecular markers CARP XI
expression differed significantly between astrocytomas
and oligodendrogliomas; all oligodendrogliomas were
negative (p = 0.040, chi-square test). In astrocytomas and
oligodendrogliomas, there were no association between
CARPs and proliferation by Ki-67 / MIB-1 (p = n.s,
Kruskal-Wallis test).
In diffuse gliomas tested for the appropriate molecular
markers CARP XI expression differed significantly be-
tween diffuse astrocytomas and oligodendrogliomas; all
oligodendrogliomas were negative (p = 0.040, chi-square
Fig. 1 Immunohistochemistry. a CARP VIII in glioblastoma (gr IV). Strongly positive cytoplasmic immunostaining in two cells (magnification
× 630). b CARP VIII in astrocytoma gr II. Moderately positive cytoplasmic staining focally (× 400). c CARP XI in astrocytoma gr III. Moderate
cytoplasmic immunostaining in most of the cells (× 630). d CARP XI in glioblastoma (gr IV), Weak and diffuse cytoplasmic staining (× 630)
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test). In diffusively infiltrating astrocytomas and oligo-
dendrogliomas, there were no association between
CARPs and proliferation by Ki-67 / MIB-1 (p = n.s,
Kruskal-Wallis test).
In gliomas, hypoxia plays a key role in the regula-
tion of tumor aggressiveness and treatment resistance.
Hypoxia-inducible factors (HIF1 and 2) enhance tumor
growth under hypoxic conditions by turning on several
hypoxia-responsive genes, such as vascular endothelial
growth factor (VEGF), epidermal growth factor receptor
(EGFR) and, importantly, CA9 which has been shown to be
strongly controlled by hypoxia also in brain tumors [32].
Both EGFR and VEGF gene amplifications are usually asso-
ciated to higher tumor grade and thus poorer outcome of
patients. In gliomas, VEGF is mainly found in perinecrotic
tumor areas. EGFR gene is amplified in 40% of the glio-
blastomas [33].
In our study, the majority of the tumors expressing ei-
ther CARP VIII or CARP XI were negative concerning
VEGF. Almost all CARP VIII-positive astrocytomas in-
versely correlated to VEGF (p = 0.005, chi-square test, n
= 197. These observations suggest that the CARPs are not
related to hypoxic conditions.
In gastrointestinal, colorectal and lung cancers, the
most intense expression of CARPs has been reported in
the tumor infiltrative border rather than in the hypoxic
center areas of the tumors [20, 22, 23]. These findings
imply that CARPs might play a specific role in tumor in-
vasion. In our study, we were not able to define the precise
intratumoral location of CARPs, because each tissue
microarray specimen contained only a single representative
area of the tumor. On the other hand, diffusely infiltrating
gliomas usually invade either individually or in small groups
of cells [34]. Obviously, analyses of larger sections or mul-
tiple intratumor biopsies are warranted to evaluate further
CARP expression separately in hypoxic and invasive areas.
Similarly, the role of tumor cell invasion should be tested in
patient derived in vitro analysis in the future studies. In
light of our increasing understanding of genetic diversity
with sub-clones of malignant tumors and stem cells, CAs
II, VII, IX and XII have been shown to be present in several
categories of brain tumors [28, 31, 35–37]. CA IX seems to
be the most interesting CA in terms of its potential role in
brain tumor diagnostics and drug therapy [35]. Its tran-
scription is facilitated by HIF-1 alpha [32]. In a recent
study, a negative correlation was found between CA IX and
enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) muta-
tion in astrocytomas [38]. In our study, no correlation was
found between CARP VIII expression and the other CAs
(p = n.s., chi-square test) or IDH1 mutations (p = n.s.,
chi-square test). Similarly, there was no correlation between
CARP XI and IDH1, nor did CARP XI correlate with the
Table 1 CARP VIII and CARP XI expression in astrocytic and oligodendroglial gliomas (WHO 2016 CNS tumor classification)
Histological type Histological
grade
CARP VIII CARP XI
Negative Weak Moderate Strong Negative Weak Moderate Strong
Pilocytic astrocytoma I 31 0 0 0 30 0 0 0
Diffuse astrocytoma, IDH-mutant II 4 1 0 0 4 0 0 0
Gemistocytic astrocytoma, IDH-mutant II 4 0 0 0 4 0 0 0
Diffuse astrocytoma, IDH-wildtype II 3 0 0 0 3 0 0 0
Diffuse astrocytoma, NOS II 24 2 7 0 30 3 0 0
Anaplastic astrocytoma, IDH-mutant III 5 0 0 0 5 0 0 0
Anaplastic astrocytoma, IDH-wildtype III 1 0 0 0 1 0 0 0
Anaplastic astrocytoma, NOS III 33 2 2 0 30 4 1 0
Glioblastoma, IDH-wildtype IV 163 8 8 4 163 12 0 0
Giant cell glioblastoma IV 3 0 1 0 4 0 0 0
Gliosarcoma IV 12 0 1 0 11 1 0 0
Glioblastoma, IDH-mutant IV 16 2 3 0 19 1 0 0
Glioblastoma, NOS IV 14 2 1 1 16 1 0 0
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted II 21 2 1 0 23 0 0 0
Oligodendroglioma, NOS II 11 2 1 0 15 0 0 0
Anaplastic oligodendroglioma, IDH-mutant and
1p/19q-codeleted
III 10 0 0 0 10 0 0 0
Anaplastic oligodendroglioma, NOS III 8 0 0 0 8 0 0 0
Oligoastrocytoma, NOS II 10 0 0 0 11 0 0 0
Anaplastic oligoastrocytoma, NOS III 18 1 1 0 18 0 1 0
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expression of CA VII, CA IX, and CA XII (p = n.s.,
chi-square test). Interestingly, the expression of CARP XI
positively correlated with the cytoplasmic CA II in astro-
cytic tumors (p = 0.037, chi-square test). Endothelial expres-
sion of CA II has been associated with neoplastic growth
and considered a potential molecule in diagnostics and
treatment of gliomas [39]. CA II is regulated mainly by fac-
tors other than hypoxia [40], which might be the case with
CARPs as well. When primary and recurrent tumors were
analyzed in different tumor types, no differences in CARP
VIII and XI was found (p = n.s., chi-square test). 1p/19q
co-deletion is an independent prognostic and predictive
marker in oligodendroglial tumors [40]. In our study, all
oligodendrogliomas (with defined 1p/19q – co-deletion)
were CARP XI negative.
From the FANTOM project, the samples where expres-
sion of the CARP VIII CAGE peak is found most strongly
are: small-cell gastrointestinal carcinoma, acute myeloid
leukemia, cerebellum, rectal cancer, and reticulocytes;
whereas the expression was extremely low in astrocytoma,
glioblastoma, and glioma samples (Additional file 1: Table
S1). Similarly, the top five samples where expression of the
CA11 CAGE peak is found most strongly are: middle tem-
poral gyrus, medial temporal gyrus, amygdala, parietal lobe,
and caudate nucleus; while also near zero in astrocytoma,
glioblastoma, and glioma (Additional file 2: Table S2). In
our study, CARP XI protein immunopositivity was ob-
served only in one case (1%) of the group of
oligodendrogliomas.
It is of interest that CARP VIII and XI are only weakly
expressed in the mature astrocytes and they are absent
in the oligodendrocytes [8]. In our study, the overall ex-
pression of the CARPs in the astrocytomas and oligo-
dendroglial tumors. Was rather weak. The most benign
tumors, pilocytic astrocytomas, did not express CARPs
at all. When the grade II-IV astrocytomas and oligo-
dendrogliomas were evaluated separately, no correlation
to WHO tumor grade was found (p = n.s, chi-square
test).
However, in a recent study the inhibition of CA8 gene
in human osteosarcoma cells sensitized the tumor cells
to cisplatin chemotherapy [24]. Since this chemotherapy
is also used in glioma treatment, it would be of interest
to analyze the effect of CA8 inhibition combined to cis-
platin in gliomas.
Our analysis of the CA8 promoter has identified a
number of putative TFBSs which may affect CA8 expres-
sion (Fig. 2). CAGE data from the FANTOM project
shows a peak near the Ensembl defined TSS. This peak
overlaps, and is supported by, an Ensembl predicted pro-
moter region. Within this promoter region our analysis
has predicted a cluster of overlapping TFBSs within an
area that is − 59 to − 41 nt upstream of the TSS. Specif-
ically, the TF proteins, which are predicted to bind here,
are KLF14, SP4, and EGR1. Two additional binding clus-
ters exist further upstream of the TSS, STAT5A:STAT5B
and STAT3 at − 524 to − 512, and a site for CEBPA,
HLF, CEBPE, CEBPD, and CEBPB at − 783 to − 771. A
complete list of predictions is available as Add-
itional file 3: Table S3.
Early growth response-1 (EGR1) has demonstrated
both tumor-suppressor and oncogene properties de-
pending on the type of tumor. In high-grade astrocy-
toma, EGR1 expression is associated with enhanced
patient survival [41]. However, Sakakini et al. recently
observed that EGR1 expression was much more consist-
ently observed in glioblastoma than in pilocytic astrocyto-
mas, that in proliferating cyclin A/OLIG2-positive cells
EGR1 was localized to the nucleus, and that this produced
increased aggressiveness and stemness [42]. Additional
links are found between glioma and STAT3 and CEBPB
TFs. Specifically, these two proteins correlate with mesen-
chymal differentiation and poor clinical outcome [43].
STAT5B inhibition reduces glioblastoma cell growth, cell
cycle progression, invasion, and migration [44]. There are
a number of candidate TFs, across three clusters of bind-
ing sites, that have established roles in astrocytoma and
glioblastoma. Based on expression values from the exten-
sive FANTOM project, we see that CA8 is expressed
highly in cerebellum (95.76 TPM) but near zero in astro-
cytoma, glioblastoma, and glioma. With the significantly
higher CA8 expression in normal brain tissues than in
tumor tissues, these putative TFBSs would make interest-
ing subjects for future study as possible repressors of CA8.
Our analysis of the CA11 promoter showed that the
strongest predicted binding sites are in two distinct clus-
ters (Fig. 2). The first cluster is comprised entirely of nu-
merous ZNF263 binding sites on the positive strand
overlapping the most highly expressed FANTOM CAGE
peak, locations + 86 to + 132 nt relative to TSS. The sec-
ond cluster of predicted TFBSs all overlap one another
immediately upstream of the same most strongly
expressed CAGE peak, and on both positive and nega-
tive DNA strands: LHX3, ARID3B, PHOX2A, PROP1,
PHOX2B, FOXB1, ARID5A, HOXD8, and HOXD9 at
locations + 64 to + 83 nt. A complete list of predictions
is available as Additional file 4: Table S4.
Compared to the CA8 promoter analysis, these pre-
dictions for potential TFBSs were more limited in their
correlation with astrocytoma. However, this makes
sense as nearly all the best scoring predictions seemed
to occupy one position. PHOX2B has been identified to
have a hypermethylated promoter in glioma, thus result-
ing in its down-regulation [45]. Similarly, a CpG locus in
the HOXD8 gene 5’ UTR is differentially hypermethy-
lated in short-term survival gliomas vs. long-term sur-
vivors [46]. Increased expression of HOXD9, the other
HOX family member predicted at this location, has
Karjalainen et al. BMC Cancer  (2018) 18:584 Page 6 of 9
been found associated with cell proliferation, and may
be a marker of glioma stem cells [47]. The prolific set
of potential ZNF263 binding sites overlapping the
CAGE peak could be a locus for CA11 repression, as
ZNF263 serves that function in some genes [48].
These two proximal sites represent potential regula-
tory sites worth investigating further to understand
the decreased expression of CA11 in astrocytoma and
oligodendroglioma.
Conclusions
Our studies showed no CARP expression in pilocytic
astrocytomas. In higher grade gliomas, the CARP
Fig. 2 Comparative genomics TFBS analysis of the CA8 and CA11 promoters. Alignments of 17 and 24 mammal sequences corresponding
to the promoters of full-length human CA8 transcript ENST00000317995 (a) and CA11 transcript ENST00000084798 (b), respectively, were
analyzed for putative transcription factor binding sites by comparative genomics. For each, the 10 best scoring transcription factors were
included in the figure, where height indicates the number of species supporting that prediction. Positive y-axis results indicate a TFBS
predicted on the positive strand while negative y-axis indicates the negative strand. Conservation of sequence in the alignment, CpG
ratio in the human sequence, and location of FANTOM CAGE peaks in the human sequence are included as subpanels. Location relative
to TSS is marked across the bottom of the figure, and is relevant for all panels
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expression is mainly absent or weak. In this study, the
CARP VIII and XI proteins were associated to
non-hypoxic conditions and CARP XI also to the ex-
pression of cytoplasmic CA II staining. The expression
of CARPs did not associate to survival or tumor WHO
grade. Due to their presence in a subset of malignant
gliomas, CARPs may have a role in tumorigenic pro-
cesses. However, further investigations on the functions
of CARPs are warranted.
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Additional file 4: Table S4. Full results of comparative genomics
prediction of TFBSs in CA11 promoter. (XLSX 105 kb)
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